Drug Profile


Alternative Names: XMMCO-791/RTA; XomaZyme-Col

Latest Information Update: 20 Feb 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Developer Cancer Research UK; Wayne State University School of Medicine; XOMA
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 20 Feb 1996 Discontinued-I for Colorectal cancer in United Kingdom (IV-infusion)
  • 20 Feb 1996 Discontinued-I for Colorectal cancer in USA (IV-infusion)
  • 04 Oct 1995 Phase-I clinical trials for Colorectal cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top